Olmesartan/Amlodipino/Hidroclorotiazida Lacer (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan/Amlodipino/Hidroclorotiazida Lacer is used in the management of hypertension, targeting several physiological pathways that regulate blood pressure.

• Hypertension: helps lower systolic and diastolic blood pressure when monotherapy is insufficient.
• Hypertensive heart disease: reduces cardiac after‑load and improves ventricular function.
• Chronic kidney disease with hypertension: slows progression of renal impairment by controlling systemic pressure.
• Stroke risk reduction: contributes to lower incidence of cerebrovascular events in high‑risk patients.
• Diabetes‑related hypertension: offers blood‑pressure control without adversely affecting glucose metabolism.

• The combination works by three complementary actions: olmesartan blocks the angiotensin II type‑1 receptor, preventing vasoconstriction; amlodipine inhibits calcium influx into vascular smooth‑muscle cells, causing arterial dilation; and hydrochlorothiazide promotes renal excretion of sodium and water, decreasing plasma volume. Together these mechanisms produce additive reductions in systemic vascular resistance and blood volume, leading to lower arterial pressure.

Side effects may occur with any antihypertensive regimen and should be monitored by a healthcare professional.

Common Side Effects

• Dizziness or light‑headedness, especially after the first doses.
• Peripheral edema, often noticeable in the ankles.
• Headache, mild to moderate in intensity.
• Flushing or warmth sensation.
• Fatigue or general tiredness.
• Increased urination due to the diuretic component.

Serious or Rare Side Effects

• Severe hypotension with fainting.
• Acute kidney injury or significant rise in serum creatinine.
• Hyperkalemia or electrolyte disturbances.
• Angio‑edema involving the face, lips, or airway.
• Liver enzyme elevations indicating hepatic stress.
• Blood cell abnormalities such as leukopenia or thrombocytopenia.

Patients should be evaluated for contraindications and monitored during therapy.

• Pregnancy: avoid use; teratogenic risk especially in the second and third trimesters.
• Renal impairment: adjust dosing and monitor kidney function regularly.
• Hepatic disease: use with caution; monitor liver enzymes.
• Electrolyte balance: check serum potassium and sodium periodically.
• Concomitant antihypertensives: may increase risk of excessive blood‑pressure lowering.
• Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Olmesartan/Amlodipino/Hidroclorotiazida Lacer can interact with several drug classes; clinicians should review patient medication lists.

Major Interactions (Avoid)

• Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, aliskiren) – risk of renal failure and hyperkalemia.
• Potassium‑sparing diuretics or supplements – may cause dangerous hyperkalemia.
• Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin) – increase amlodipine levels.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – may blunt antihypertensive effect and affect renal function.
• Lithium – increased risk of lithium toxicity.
• Antidiabetic agents – may require dose adjustment due to enhanced glucose‑lowering effect.
• Alcohol – additive blood‑pressure lowering and dizziness.
• Rifampin – may reduce effectiveness of amlodipine.